Hangzhou Gaocheng Biotech & Health CO., LTD

Hangzhou Gaocheng Biotech & Health Co., Ltd is a Chinese manufacturer and exporter established in Hangzhou in 1994. The company operates with GMP-standard facilities and a dedicated production plant equipped to support advanced pharmaceutical pellet production. As a vertically integrated operation, Gaocheng Biotech & Health focuses on creating pellets that serve as cores for various pharmaceutical and health-related applications, including sustained and controlled-release drug delivery technologies. The company emphasizes a range of pellet products designed to meet global pharmaceutical standards and regulatory expectations.

Core offerings include three principal drug pellet varieties used in pharmaceutical formulations: Sugar Sphere, Microcrystalline Cellulose Pellet, and Starch Pellet. Each pellet type is developed to accommodate controlled and sustained release profiles, enabling manufacturers to formulate dosage forms with predictable drug release kinetics. The pellets are sized between 0.1 mm and 1.12 mm, a spectrum that supports multiple processing routes in downstream pharmaceutical production, hygienic pellets, and cosmetic applications. The firm states that its pellet standards align with recognized pharmaceutical compendia, specifically USP, BP, and EP, signaling a commitment to international quality benchmarks and compatibility with global customers’ regulatory needs.

Gaocheng Biotech & Health positions its pellets as versatile core materials that can be employed by pharmaceutical manufacturers worldwide. The company highlights that its products are utilized not only as components in pellet-based dosage forms but also as encapsulated materials that help preserve active ingredients from oxidation and other degradation pathways. This encapsulation capability is presented as a value-added service, offering protection to contents against moisture, taste characteristics, and other potential formulation challenges.

Beyond core pellets, the company reports the ability to produce pellet variants tailored to specific dosage forms. Examples mentioned include ferrous sulfate pellets, diclofenac sodium pellets, omeprazole pellets, and ibuprofen pellets. This capability suggests a flexible manufacturing approach that can adapt to custom formulations and customer specifications. Gaocheng Biotech & Health emphasizes its reach across markets, noting traction in regions such as Korea, which points to established export activity and international distribution networks.

Encapsulization services form another pillar of Gaocheng Biotech & Health’s offering. The company claims to provide encapsulation according to client requirements, including control over particle size and release profiles. Encapsulated pellets are described as a means to maintain content integrity by mitigating oxidation, moisture sensitivity, bitterness, and related formulation challenges. The breadth of microencapsulation capabilities is indicated through references to a variety of microcapsule products, including folic acid pellets and citric acid pellets, reflecting a broader portfolio within the specialty chemicals and pharmaceutical excipients landscape.

In terms of product performance, the company notes that the content of its vitamin-related pellets and sustained-release formulations can be maintained at or above 90% over a two-year period. This claim suggests a focus on stability, quality retention, and long shelf life for its pellet products, aligning with the expectations of manufacturers seeking reliable excipients and core materials for their dosage forms. The company also signals the possibility of customization, indicating that release curves and timing can be adjusted to meet particular product specifications. By offering such customization, Gaocheng Biotech & Health positions itself as a partner capable of supporting customers through different development and scale-up stages, from pilot batches to larger production runs.

As a supplier with domestic manufacturing roots and an export-oriented posture, Gaocheng Biotech & Health appears to prioritize quality assurance, regulatory compliance, and technical flexibility. The firm’s emphasis on GMP standards and international pharmacopoeia alignment underlines their intent to serve global customers who require consistent performance and robust documentation for cross-border supply chains. While the core business revolves around pharmaceutical pellets and related encapsulation technologies, the company’s export orientation implies capabilities in coordinating logistical workflows, packaging considerations suited to pharmaceutical materials, and efficient handoffs to downstream distributors or contract manufacturers.

For potential partners and buyers, Gaocheng Biotech & Health offers a portfolio that blends material science with practical processing capabilities. The pellet formats and encapsulation options described suggest compatibility with a range of downstream manufacturing processes, including pellet-based tablet cores, multipartite dosage forms, and other applications where precise release control is critical. The company’s stated international footprint, including activity in Korea, signals an established readiness to engage with foreign customers and navigate the regulatory and supply-chain requirements typical of the global pharmaceutical supply network.

Given the information available, Hangzhou Gaocheng Biotech & Health Co., Ltd presents itself as a credible source for pharmaceutical pellet cores and encapsulated pellet solutions, backed by GMP-compliant facilities and a track record of meeting international standards. While the primary focus is manufacturing and export of pellet products, the company’s capabilities in customization, release-control technologies, and stability-focused formulations may offer value to partners seeking reliable excipients and core materials for new or existing pharmaceutical formulations. Prospective collaborators are encouraged to initiate direct discussions to confirm technical specifications, regulatory documentation, quality assurance practices, and logistics arrangements tailored to their specific product development and supply-chain needs.